Cefepime: Difference between revisions

Revision as of 14:49, 18 December 2013

Cefepime
MAXIPIME^® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings
Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
Compatibility, Reconstitution, and Stability
Directions for Use
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cefepime (INN) (IPA: Template:IPA) is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both Gram-negative and Gram-positive organisms than third-generation agents. Cefepime hydrochloride was first marketed in 1994 and is currently marketed under various trade names including Maxipime (Elan Pharma), Maxcef, Cepimax, Cepimex, and Axepim.

US Brand Names

Maxipime^®

FDA Package Insert

Mechanisms of Action

References

@@ Line 1: / Line 1: @@
-{{drugbox |
+__NOTOC__
-|width=300
+{{Cefepime}}
-|IUPAC_name = (6''R'',7''R'',''Z'')-<br />7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-<br />3-((1-methylpyrrolidinium-1-yl)methyl)-8-oxo-5-thia-<br />1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate
+{{CMG}}
-|CAS_number = 88040-23-7
-| ATC_prefix=J01
-| ATC_suffix=DE01
-| PubChem=68606
-| DrugBank=
-| C = 19 |H = 24 |N = 6 |O = 5 |S = 2
-|molecular_weight = 480.56 [[Gram|g]]/[[Mole (unit)|mol]]
-|bioavailability = 100% ([[intramuscular|IM]])
-|metabolism = [[Liver|Hepatic]] 15%
-|elimination_half-life = 2 hours
-|excretion = [[Kidney|Renal]] 70–99%
-|pregnancy_category = B1 <small>([[Australia|Au]])</small>
-|legal_status = S4 <small>(Au)</small>
-|routes_of_administration = [[Intravenous therapy|Intravenous]], [[Intramuscular injection|intramuscular]]
-}}
-{{SI}}
+==Overview==
+Cefepime ([[International Nonproprietary Name|INN]]) ([[International Phonetic Alphabet|IPA]]: {{IPA|[ˈkɛfəpim, ˈsɛfə-]}}) is a fourth-generation [[cephalosporin]] [[antibiotic]] developed in [[1994]]. Cefepime has an extended spectrum of activity against [[Gram-positive]] and [[Gram-negative]] [[bacteria]], with greater activity against both Gram-negative and Gram-positive organisms than third-generation agents. '''Cefepime hydrochloride''' was first marketed in [[1994]] and is currently marketed under various trade names including '''Maxipime''' ([[Elan Pharma]]), Maxcef, Cepimax, Cepimex, and Axepim.
-'''Cefepime''' ([[International Nonproprietary Name|INN]]) ([[International Phonetic Alphabet|IPA]]: {{IPA|[ˈkɛfəpim, ˈsɛfə-]}}) is a fourth-generation [[cephalosporin]] [[antibiotic]] developed in [[1994]]. Cefepime has an extended spectrum of activity against [[Gram-positive]] and [[Gram-negative]] [[bacteria]], with greater activity against both Gram-negative and Gram-positive organisms than third-generation agents. '''Cefepime hydrochloride''' was first marketed in [[1994]] and is currently marketed under various trade names including '''Maxipime''' ([[Elan Pharma]]), Maxcef, Cepimax, Cepimex, and Axepim.
+==Category==
+Cephalosporin, Fourth-Generation
-== Clinical use ==
+==US Brand Names==
-{{dablink|Main article: [[Cephalosporin]]}}
+Maxipime<sup>®</sup>
-Cefepime is usually reserved to treat severe [[nosocomial]] [[pneumonia]], infections caused by multi-resistant microorganisms (e.g. ''[[Pseudomonas aeruginosa]]'') and [[empirical]] treatment of [[febrile]] [[neutropenia]].{{ref|Chapman}} The use of cefepime might become less common, since it has been associated to an increase mortality when used for different types of infections.
-Cefepime has good activity against important pathogens including ''Pseudomonas aeruginosa'', ''[[Staphylococcus aureus]]'', and multiple drug resistant ''[[Streptococcus pneumoniae]]''. A particular strength is its activity against ''[[Enterobacteriaceae]]''. Whereas other cephalosporins are degraded by many [[plasmid]]- and [[chromosome]]-mediated [[beta-lactamase]]s, cefepime is stable and is a front line agent when infection with Enterobacteriaceae is known or suspected.
+==FDA Package Insert==
+'''[[Cefepime description|Description]]'''
+'''| [[Cefepime clinical pharmacology|Clinical Pharmacology]]'''
+'''| [[Cefepime microbiology|Microbiology]]'''
+'''| [[Cefepime indications and usage|Indications and Usage]]'''
+'''| [[Cefepime contraindications|Contraindications]]'''
+'''| [[Cefepime warnings|Warnings]]'''
+'''| [[Cefepime precautions|Precautions]]'''
+'''| [[Cefepime adverse reactions|Adverse Reactions]]'''
+'''| [[Cefepime overdosage|Overdosage]]'''
+'''| [[Cefepime clinical studies|Clinical Studies]]'''
+'''| [[Cefepime dosage and administration|Dosage and Administration]]'''
+'''| [[Cefepime compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]'''
+'''| [[Cefepime directions for use|Directions For Use]]'''
+'''| [[Cefepime how supplied|How Supplied]]'''
+'''| [[Cefepime other size packages available|Other Size Packages Available]]'''
+'''| [[Cefepime labels and packages|Labels and Packages]]'''
-== Chemistry ==
+==Mechanisms of Action==
-The combination of the ''syn''-configuration of the [[methoxy]][[imino]] [[moiety]] and the [[amino]][[thia]]zolyl moiety confers extra stability to [[beta lactamase|&beta;-lactamase]] enzymes produced by many bacteria.  The ''N''-[[methyl]][[pyrrolidine]] moiety increases penetration into Gram-negative bacteria. These factors increases the activity of cefepime against otherwise resistant organisms including ''Pseudomonas aeruginosa'' and ''Staphylococcus aureus''.
-== References ==
-{{note|Chapman}} Chapman TM, Perry CM. ''Cefepime: a review of its use in the management of hospitalized patients with pneumonia.'' Am JRespir Med. 2003;2(1):75-107. PMID 14720024
-{{note|Yahav}} Yahav, D et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet 2007; 7:338-348.
-== See also ==
+==References==
-*[[Cephalosporin]]
+{{Reflist|2}}
-== External links ==
+[[Category:Antibiotics]]
-*[http://www.elan.com/products/united_states/maxipime_fact_sheet.asp Maxipime fact sheet – Elan Pharmaceuticals]
+[[Category:Wikinfect]]
-{{CephalosporinAntiBiotics}}
-[[Category:Cephalosporin antibiotics]]
-[[es:Cefepima]]
-[[th:เซฟีพิม]]
-{{WikiDoc Help Menu}}
-{{WS}}